CINECA IRIS Institutional Research Information System

D'AVOLIO, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.100
EU - Europa 16.303
AS - Asia 6.896
SA - Sud America 203
AF - Africa 200
OC - Oceania 87
Continente sconosciuto - Info sul continente non disponibili 46
Totale 52.835
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.827
DK - Danimarca 3.936
CN - Cina 3.121
IT - Italia 2.837
SG - Singapore 1.948
IE - Irlanda 1.683
SE - Svezia 1.454
FR - Francia 1.233
DE - Germania 1.185
FI - Finlandia 842
UA - Ucraina 736
GB - Regno Unito 606
AT - Austria 566
KR - Corea 479
VN - Vietnam 331
PL - Polonia 318
IN - India 272
CA - Canada 217
NL - Olanda 211
ID - Indonesia 170
ES - Italia 158
JP - Giappone 144
BE - Belgio 137
HK - Hong Kong 93
ZA - Sudafrica 92
AU - Australia 80
BR - Brasile 80
CZ - Repubblica Ceca 78
TH - Thailandia 61
TW - Taiwan 53
RU - Federazione Russa 52
CL - Cile 48
CH - Svizzera 43
GR - Grecia 43
RO - Romania 43
MX - Messico 42
EU - Europa 38
TR - Turchia 38
PK - Pakistan 33
CO - Colombia 31
UZ - Uzbekistan 29
EG - Egitto 27
PT - Portogallo 25
IR - Iran 19
AR - Argentina 17
RS - Serbia 16
SN - Senegal 16
HU - Ungheria 15
NG - Nigeria 15
HR - Croazia 14
IL - Israele 14
PE - Perù 12
NO - Norvegia 11
MY - Malesia 10
SA - Arabia Saudita 10
EC - Ecuador 9
KE - Kenya 9
PH - Filippine 9
BG - Bulgaria 8
IQ - Iraq 8
LT - Lituania 8
AE - Emirati Arabi Uniti 7
AP - ???statistics.table.value.countryCode.AP??? 7
NZ - Nuova Zelanda 7
QA - Qatar 7
CR - Costa Rica 6
KZ - Kazakistan 6
BA - Bosnia-Erzegovina 5
EE - Estonia 4
GH - Ghana 4
JO - Giordania 4
LV - Lettonia 4
MD - Moldavia 4
ME - Montenegro 4
MO - Macao, regione amministrativa speciale della Cina 4
MU - Mauritius 4
PS - Palestinian Territory 4
SI - Slovenia 4
SK - Slovacchia (Repubblica Slovacca) 4
TN - Tunisia 4
AL - Albania 3
AZ - Azerbaigian 3
BY - Bielorussia 3
BZ - Belize 3
CI - Costa d'Avorio 3
DZ - Algeria 3
LK - Sri Lanka 3
MA - Marocco 3
MK - Macedonia 3
MW - Malawi 3
TZ - Tanzania 3
UG - Uganda 3
BD - Bangladesh 2
BO - Bolivia 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LI - Liechtenstein 2
Totale 52.805
Salva come PNG Salva come JPEG
Città #
Ann Arbor 7.857
Chandler 2.995
Beijing 1.924
Dublin 1.676
Singapore 1.608
Santa Clara 1.491
Fairfield 1.088
Houston 1.061
Ashburn 892
Villeurbanne 871
Torino 793
Wilmington 736
Dearborn 716
Woodbridge 627
Nyköping 616
Princeton 578
Medford 557
Vienna 499
Jacksonville 496
Columbus 473
Seattle 464
Cambridge 351
Redwood City 347
Warsaw 283
Fremont 267
Turin 242
Milan 198
New York 183
Pisa 175
Boston 171
Dong Ket 166
Jakarta 150
Boardman 148
Guangzhou 137
Brussels 103
Shanghai 103
Toronto 102
Nanjing 96
Munich 93
Verona 78
Hefei 75
Helsinki 75
Los Angeles 73
Hangzhou 71
Norwalk 71
San Diego 71
Washington 58
Rome 54
Brno 52
Paris 50
Falls Church 49
Kunming 49
Hong Kong 47
Jinan 46
London 42
Hebei 36
Pune 36
Chengdu 35
Mountain View 35
Taipei 35
Dallas 34
Phoenix 34
Cape Town 32
Chicago 32
Edinburgh 32
Nürnberg 29
Tokyo 29
Nanchang 28
Philadelphia 28
Seoul 28
Kharkiv 26
Barcelona 25
Ottawa 25
Amsterdam 24
Bologna 24
Montreal 24
San Mateo 24
Santiago 24
Silver Spring 24
Des Moines 22
Frankfurt am Main 22
Genoa 22
Madrid 22
Mumbai 22
Zhengzhou 22
Shenzhen 21
Lappeenranta 20
Nuremberg 20
Wuhan 20
Grafing 19
Changsha 18
Florence 18
Buffalo 17
Hyderabad 16
Lachine 16
Montréal 16
Stockholm 16
Chongqing 15
Fuzhou 15
Minneapolis 15
Totale 33.391
Salva come PNG Salva come JPEG
Nome #
Pharmacokinetics of linezolid during extracorporeal membrane oxygenation 901
Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. 437
UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. 406
Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children 400
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. 383
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients 356
Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. 341
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 329
The E genotype of hepatitis B: Clinical and virological characteristics, and response to interferon 319
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 315
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs 314
Ceftriaxone bone penetration in patients with septic non-union of the tibia 301
A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics? 293
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 291
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting 286
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 284
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). 281
Raltegravir penetration in seminal plasma of healthy volunteers. 257
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study 256
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 255
Anidulafungin for Candida glabrata Infective Endocarditis 253
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) 244
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 243
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. 242
Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis. 239
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 239
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 238
Ultra Performance Liquid Chromatography PDA Method for Determination of Tigecycline in Human Plasma. 235
A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease 234
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 233
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 232
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 223
Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH 218
Pharmacogenetics of Antiretrovirals' Penetrations into Cerebrospinal Fluid 211
Bioanalytical method validation of quantitative mass spectrometry based assay: experimental protocols and regulations 209
Descrittiva della farmacocinetica (PK) e della farmacogenetica (PG) dell'Efavirenz in una coorte di popolazione italiana 203
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 202
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients 201
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. 199
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 197
Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B 196
Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment 195
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. 191
Development of Standard Operating Protocols for the Optimization of Cannabis-Based Formulations for Medical Purposes 187
THE HOCT1/ABCB1 DIPLOTYPE IS ASSOCIATED WITH COMPLETE CYTOGENETIC RESPONSE AND TOLERABILITY TO IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA 185
Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. 184
Il dosaggio dei farmaci immunosoppressori: tecnologie a confronto. 184
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens 183
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients 183
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 183
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 182
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 181
Enhancement of calcyclin gene RNA expression in squamous cell carcinoma of the oral mucosa, but not in benign lesions 181
L-histidine/medroxyprogesterone acetate interaction modulates human breast cancer cell growth and progestin receptor expression in vitro. 179
ITPA gene variants as markers of ribavirin-induced anemia and white blood cells reduction in Egyptian HCV patients 179
Antibiotic diffusion in pseudoarthrosic infected bone: glycopeptides, fluoroquinolones and carbapenems 178
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 178
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 177
PHARMACOGENETIC DETERMINANTS OF PLASMATIC AND INTRACELLULAR TYROSINE KINASE INHIBITORS 177
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 177
Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines. 176
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E. 176
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 176
Role of pharmacogenetics on deferasirox AUC and efficacy 175
Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia 173
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 173
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 172
Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. 171
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. 170
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting 170
Farmacocinetica dell’anidulafungina in pazienti con fibrosi cistica, trapianto epatico e emodiafiltrazione: dati preliminari. 169
Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study 169
Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia 169
Effect of multidrug-resistant gene polymorphisms on daptomycin concentrations: preliminary results 168
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 167
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 167
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D 166
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. 166
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting 165
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 165
Antihypertensive Bridge Therapy by Continuous Drug Infusion with an Elastomeric Pump in Device-Resistant Hypertension 165
Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. 164
Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification 164
SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir 163
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 163
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 163
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. 163
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 163
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. 163
PHISIOLOGIC VARIABLES AND PHARMCOKINETICS IMIPENEM DURING ENLP. A SINGLE CENTER TRANSPLANTATION EXPERIENCE 163
Genetic determinants of mitotane pharmacokinetics in adrenocortical cancer patients 162
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 162
Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia 161
Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia 161
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. 160
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. 159
An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients 158
Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients 158
Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults 158
New hplc-mass spectrometry method for the simultaneous quantification in human plasma of the antileukemia drugs imatinib, dasatinib, and nilotinib 158
Totale 21.794
Salva come PNG Salva come JPEG
Categoria #
all - tutte 152.106
article - articoli 0
book - libri 0
conference - conferenze 44.719
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 196.825
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.191 0 0 0 0 0 0 797 416 504 969 1.128 1.377
2020/20215.802 1.071 232 189 336 403 363 347 190 484 399 553 1.235
2021/202210.908 958 899 944 1.050 797 911 1.081 888 611 364 1.231 1.174
2022/20238.915 894 625 231 823 875 2.211 580 710 934 174 571 287
2023/20243.507 441 584 206 184 238 502 114 212 58 166 280 522
2024/20255.198 149 463 411 906 2.540 720 9 0 0 0 0 0
Totale 55.375